GLP-1 receptor agonists in type 2 diabetes: An underused asset? (2020)

Type of publication:
Journal article

Author(s):
*Morris, David

Citation:
Journal of Diabetes Nursing; Aug 2020; vol. 24 (no. 5); p. 1-11

Abstract:
As our understanding of the incretin hormone system has increased, a number of drugs targeting this system
have been developed. The realisation of this potential has developed rapidly, and glucagon-like peptide-1
receptor agonists (GLP-1 RAs) are now a standard feature in management guidelines for type 2 diabetes. This
article reviews the operation of the incretin system and the mechanism by which GLP-1 RAs act to provide
benefit in type 2 diabetes. The availability and indications for use of the GLP-1 RAs, and their clinical benefits
and disadvantages, are summarised. The position of GLP-1 RAs in the management of type 2 diabetes is
discussed pragmatically, with reference to various key guidelines.